Blood testing has the potential to transform #ColorectalCancer screening, and the FDA approval of our Shield test for people age 45+ at average risk is a major step forward for the 50 million people in the U.S. who are not up to date with screening. Thank you to our clinical and medical partners, to the people who participate in our studies and to our team at Guardant for making this moment possible! More details: https://lnkd.in/expTfVEJ
Guardant Health
Biotechnology Research
Palo Alto, California 170,577 followers
Conquering Cancer With Data
About us
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
- Website
-
https://guardanthealth.com/
External link for Guardant Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2012
Locations
Employees at Guardant Health
Updates
-
Happy #NationalInternDay to all of our amazing Guardant Interns! Today, we celebrate your dedication and impact. Your hard work and fresh perspectives play a vital role in advancing our mission to conquer cancer with data.
Late post but I wanted to highlight the amazing time we had at the San Francisco Giants game in early July with our fantastic 2024 Guardant Health Interns! ⚾ It was a wonderful opportunity for our interns to bond, network, and enjoy the best stadium in baseball! Here's to building connections and creating lasting memories. #GuardantHealth #Internship2024 #TeamBuilding #SanFranciscoGiants
-
-
Kirk shares his journey with being diagnosed with Stage IV lung cancer and how Guardant360 helped navigate his treatment plan, allowing him to live life fully on his own terms. Explore more of Kirk's story: https://lnkd.in/gg3abyJi
-
Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10 times more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity. “Guardant360 is the leading liquid biopsy test for patients with advanced cancer, and this major upgrade through our Guardant Infinity smart liquid biopsy platform enables us to give oncologists a much more complete view of cancer,” said co-CEO Helmy Eltoukhy. Read the full release: https://lnkd.in/en5UR-ag
-
-
Len Lichtenfeld MD MACP emphasizes the urgent need for new colorectal cancer (CRC) screening options in his latest article for Healthcare Innovation . As we strive for improved patient outcomes and accessibility, exploring innovative approaches is essential. Read more of this important perspective.
It’s Time for a New Option in Colorectal Cancer Screening
hcinnovationgroup.com
-
Passionate about gaining access to standardized, robust liquid biopsy testing globally? Join us for a discussion with Jean-Francois Martini, head of biomarker clinical assay and technology at Pfizer, and Lawrence Wang, chief financial officer at Adicon Clinical Laboratories to hear about the importance of LBx testing for global clinical trials and how we're successfully enabling in-country testing. 📅 Date: July 25 🕦 Time: 11:30am ET Registration: bit.ly/3XXGBnU
-
-
Via STAT: Blood tests for cancer patients are proving to be life-saving, but accessibility remains an issue. Our co-CEO Helmy Eltoukhy outlines the barriers and why ensuring equitable access is essential to improving patient outcomes.
Blood Tests for Cancer Patients Save Lives. Access Remains an Issue.
https://www.statnews.com
-
Colorectal cancer is highly treatable if caught early. Yet, despite having screening options available, a staggering 50 million people – approximately one in three eligible Americans – are not up to date with recommended screening. Recently an FDA committee endorsed a new blood test as a primary non-invasive screening option. It has the potential to motivate more patients to be screened and ultimately save more lives. We, the undersigned, urge policymakers, health care professionals, and our fellow advocates to rally behind this groundbreaking technology and give patients more screening options. Signatories: Colorectal Cancer Alliance, Alliance for Women's Health & Prevention, Cancer Advocacy Group of Louisiana (CAGLA), Colon Cancer Stars, First Ladies Health Initative, Global Colon Cancer Association, GI Cancers Alliance, MAN UP TO CANCER, The Raymond Foundation, Inc., Colon Cancer Coalition, PALTOWN Development Foundation, The Blue Hat Foundation, One Cancer Place
Don't Let Perfect Become the Enemy of Good in Colorectal Cancer Screening
thehill.com
Similar pages
Browse jobs
Stock
GH
NASDAQ
20 minutes delay
$33.00
1.07 (3.351%)
- Open
- 32.73
- Low
- 31.8
- High
- 33.53
Data from Refinitiv
See more info on